A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Patients With Schizophrenia
The primary purpose is to evaluate the safety and tolerability of ASP6981 in participants with schizophrenia.
Also primary purpose is to evaluate the pharmacodynamics of ASP6981 in participants with schizophrenia as measured by cognitive function and neurophysiological biomarkers.
The secondary purpose of this study is to evaluate the pharmacokinetics of ASP6981 in participants with schizophrenia.
100 项与 ASP-6981 相关的专利(医药)